---
schema_version: "secwatch.filing_event.v1"
accession: "0000947871-23-000333"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:25:43.179903+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics updates 2023-2026 outlook: mid single-digit revenue CAGR, high single-digit adjusted EPS CAGR

## Summary
- Reiterates 2023 guidance: revenue $8.83B-$9.03B, base business +2.6%-3.8%, adjusted EPS $8.40-$9.00.
- Long-term 2023-2026: mid single-digit revenue CAGR; high single-digit adjusted EPS CAGR.
- Invigorate program targets ~3% annual productivity savings via automation, AI, and digital.
- Growth initiatives: physician/hospital expansion, molecular genomics, oncology, consumer health.
- No change to 2023 guidance; capital deployment strategy discussed without new commitments.

## SEC filing metadata
- accession: 0000947871-23-000333
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000094787123000333/0000947871-23-000333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000094787123000333/ss1867887_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000947871-23-000333
- JSON: https://secwatch.observer/filing/0000947871-23-000333.json
- Plain text: https://secwatch.observer/filing/0000947871-23-000333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.